menu toggle

January 9, 2026

Now available CIMERLI®

CIMERLIĀ® (ranibizumab-eqrn) injection, for intravitreal use, is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with:
- Neovascular (Wet) Age-Related Macular Degeneration (AMD) 
- Macular Edema Following Retinal Vein Occlusion (RVO) 
- Diabetic Macular Edema (DME)
- Diabetic Retinopathy (DR)
- Myopic Choroidal Neovascularization (mCNV)


View full prescribing information.